drugset / Trial / NCT01636492

A Study of Bitopertin (RO4917838) in Healthy Male Volunteers

NCT01636492

Phase 1 Completed 71 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blind

Summary

This randomized, double-blind, placebo-controlled, dose-escalating study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of bitopertin in healthy male volunteers. Subjects will be randomized in cohorts to receive single oral doses of either bitopertin or placebo.

Timeline

Start
2005-11
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject bitopertin Small molecule Oral

Indications

No indication recorded.